Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
December 13, 2021 06:00 ET
|
Foghorn Therapeutics, Inc.
- Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery...
Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference
November 11, 2021 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression...
Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
September 01, 2021 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene...
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
August 23, 2021 07:00 ET
|
Foghorn Therapeutics, Inc.
FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9 Foghorn’s first protein degrader program to enter the clinic; continues pre-clinical work on other protein degrader...
Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
August 10, 2021 07:00 ET
|
Foghorn Therapeutics, Inc.
-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) -- IND Clearance for...
Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
August 03, 2021 08:30 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
July 09, 2021 08:36 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
June 08, 2021 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics to Present in Two Upcoming Investor Conferences
May 26, 2021 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
May 17, 2021 07:00 ET
|
Foghorn Therapeutics, Inc.
- First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system - FHD-286 is a highly potent, selective, allosteric, oral, small molecule inhibitor of...